This Week's BioHealth & Biotech Top Stories
We saw another exciting week full of news for key developments in drug stocks, biotech stocks, medical device stocks, and other companies involved in various aspects of health care and medicine. Below are some of the stock tickers we covered over at BioHealthInvestor.com this week:
- STOCK TICKERS: ABT, BSX, MDT, JNJ, SRDX, ANPI, BAYRY, MAXY, AMGN, CRA, INGN, CELG, MRK, SNY, GSK, AKRX, ARYX
This week we saw another FDA Approval in stents as Abbott’s (NYSE: ABT) XIENCE drug-eluting coronary stent was approved for marketing. While this is causing a resurgence in stents, this space is about to become highly competitive (stocks covered: ABT, BSX, MDT, JNJ, SRDX, ANPI). Introgen (NASDAQ: INGN) has a new twist for head and neck cancer… give it a cold, literally. Celgene Corp. (NASDAQ: CELG) actually won out as a competitor’s bone marrow disease trials failed to meet expectations. Merck (NYSE: MRK) was an FDA decision winner as it gets to keep its lead on the cervical cancer vaccine market in the U.S. tied up for at least 6-months longer than it was anticipated (stocks covered: MRK, SNY, GSK).
This may be a tiny company, but a patent was awarded in bone marrow and stem cell transplants. While a biotech turned over its hemophelia treatments to a larger company, hemophelia treatments may be better off now (stocks covered: BAYRY, MAXY, AMGN). Vaccine awards are going to keep sales up at one small vaccine maker. One Alzheimer’s Disease treatment that originally had high hopes has bitten the dust. P&G walked away from a partner this week, killing a tiny biotech (stocks covered: PG, ARYX).
And on the front for reviews:
- Do you remember all the hype and hopes for synthetic blood? This looks like the last player has gone on to greener pastures.
- What is a good investment that has backed way off from highs that should show steady growth in the China health care sector? We evaluated one potential company for this.
These issues are more stock issues than anything else:
- Celera Corporation (NASDAQ: CRA) completed its journey to independence and took its 3-letter ticker over to NASDAQ.
- Bayhill Therapeutics withdrew its plans for an IPO. MS and diabetes patients will have to look elsewhere, for now.
Have a happy and safe LONG Fourth of July weekend. I think there is a new treatment on the market for burnt hand trauma from fireworks, but the FDA has it on hold until next February.
Jon C. Ogg
July 4, 2008